Status:
COMPLETED
Postpartum Glycemia in Women At Risk for Persistent Hyperglycemia
Lead Sponsor:
University of Alabama at Birmingham
Collaborating Sponsors:
University of North Carolina, Chapel Hill
Conditions:
Gestational Diabetes
Eligibility:
FEMALE
18-45 years
Phase:
NA
Brief Summary
GDM is characterized by decreased insulin sensitivity, decreased insulin secretion, or a combination of both. Women with GDM are at significant risk for overt T2DM later in life, and postpartum insuli...
Eligibility Criteria
Inclusion
- Inclusion Criteria for early GDM women:
- Live singleton gestation with no fetal anomalies at 34-40 weeks gestation
- Gestational diabetes mellitus identified at \< 20 weeks' gestation requiring pharmacologic treatment (class A2)
- Exclusion Criteria for early GDM women:
- History of prediabetes or polycystic ovarian syndrome
- History of pregestational type 2 diabetes mellitus
- Skin conditions which prevent wearing a continuous glucose monitor
- Inclusion Criteria for 3rd trimester GDM women:
- Live singleton gestation with no fetal anomalies at 34-40 weeks gestation
- Gestational diabetes mellitus identified at \>= 24 weeks' gestation requiring pharmacologic treatment (class A2)
- Exclusion Criteria for 3rd trimester GDM women:
- History of prediabetes or polycystic ovarian syndrome
- History of pregestational type 2 diabetes mellitus
- Skin conditions which prevent wearing a continuous glucose monitor
Exclusion
Key Trial Info
Start Date :
September 17 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 10 2024
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04521712
Start Date
September 17 2021
End Date
December 10 2024
Last Update
December 18 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35233
2
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States, 27514